Literature DB >> 28958075

Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder.

Nadya Pyatigorskaya1,2,3, Rahul Gaurav1, Dario Arnaldi1,4, Smaranda Leu-Semenescu5, Lydia Yahia-Cherif1,2, Romain Valabregue1,2, Marie Vidailhet2,6,7, Isabelle Arnulf2,5, Stephane Lehéricy1,2,3.   

Abstract

Objectives: Idiopathic rapid eye movement sleep behavior disorder (iRBD) is considered to be a prodromal stage of Parkinson's disease (PD). At PD onset, 40 to 70% of the dopaminergic neurons in the substantia nigra (SN) are already lost. Thus, milder SN damage is expected in participants with iRBD. We aimed to quantify SN damage in participants with iRBD using multimodal magnetic resonance imaging (MRI) and to determine biomarker efficacy in preclinical Parkinsonism.
Methods: Nineteen participants with iRBD and 18 controls underwent 3-Tesla MRI, including diffusion tensor imaging, neuromelanin (NM)-sensitive imaging, and T2* mapping. Regions of interest in the SN area were drawn in NM-sensitive and T2-weighted images. The volume and normalized signal intensity in NM-sensitive images, R2*, and diffusion tensor measures were quantified in the SN. Additionally, two raters performed visual analysis of the SN using the NM-sensitive images.
Results: Participants with iRBD showed a reduction in the NM-sensitive volume and signal intensity and a decrease in fractional anisotropy (FA) versus controls, but showed no differences in axial, radial, or mean diffusivity or in R2*. For NM-sensitive volume and signal intensity, the receiver operating characteristic analysis discriminated between participants with iRBD and controls with a diagnostic accuracy of 0.86 and 0.79, respectively, whereas the accuracy was 0.77 for FA. The three biomarkers had a combined accuracy of 0.92. The fraction of participants correctly characterized by visual assessment was 0.81. Conclusions: NM-sensitive imaging and FA allowed for the detection of SN damage in participants with iRBD with good diagnostic accuracy. These measures may represent valuable biomarkers for prodromal Parkinsonism. © Sleep Research Society 2017. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Parkinson’s disease; REM sleep behavior disorder; brain imaging; movement disorders; neuroimaging; neuromelanin; sleep and neurodegenerative disorders; substantia nigra

Mesh:

Substances:

Year:  2017        PMID: 28958075     DOI: 10.1093/sleep/zsx149

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  13 in total

Review 1.  Biomarkers of Parkinson's disease: 20 years later.

Authors:  Rezzak Yilmaz; Franziska Hopfner; Thilo van Eimeren; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2019-04-04       Impact factor: 3.575

2.  Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinson's disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT.

Authors:  Hiroto Takahashi; Nobuo Kashiwagi; Atsuko Arisawa; Chisato Matsuo; Hiroki Kato; Hiroyoshi Adachi; Yuta Kajiyama; Hideki Mochizuki; Noriyuki Tomiyama
Journal:  Br J Radiol       Date:  2021-11-26       Impact factor: 3.039

Review 3.  Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review.

Authors:  Trina Mitchell; Stéphane Lehéricy; Shannon Y Chiu; Antonio P Strafella; A Jon Stoessl; David E Vaillancourt
Journal:  JAMA Neurol       Date:  2021-10-01       Impact factor: 29.907

4.  Longitudinal trimodal imaging of midbrain-associated network degeneration in Parkinson's disease.

Authors:  Kenan Steidel; Marina C Ruppert; David J Pedrosa; Carsten Eggers; Andrea Greuel; Masoud Tahmasian; Franziska Maier; Jochen Hammes; Thilo van Eimeren; Lars Timmermann; Marc Tittgemeyer; Alexander Drzezga
Journal:  NPJ Parkinsons Dis       Date:  2022-06-22

5.  The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.

Authors:  Emma Biondetti; Mathieu D Santin; Romain Valabrègue; Graziella Mangone; Rahul Gaurav; Nadya Pyatigorskaya; Matthew Hutchison; Lydia Yahia-Cherif; Nicolas Villain; Marie-Odile Habert; Isabelle Arnulf; Smaranda Leu-Semenescu; Pauline Dodet; Miquel Vila; Jean-Christophe Corvol; Marie Vidailhet; Stéphane Lehéricy
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

Review 6.  The prodromes of Parkinson's disease.

Authors:  Richard Nathaniel Rees; Alastair John Noyce; Anette Schrag
Journal:  Eur J Neurosci       Date:  2018-12-05       Impact factor: 3.386

7.  Nigrosome 1 imaging in REM sleep behavior disorder and its association with dopaminergic decline.

Authors:  Thomas R Barber; Ludovica Griffanti; Kevin M Bradley; Daniel R McGowan; Christine Lo; Clare E Mackay; Michele T Hu; Johannes C Klein
Journal:  Ann Clin Transl Neurol       Date:  2019-12-09       Impact factor: 5.430

Review 8.  Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.

Authors:  Mitchell G Miglis; Charles H Adler; Elena Antelmi; Dario Arnaldi; Luca Baldelli; Bradley F Boeve; Matteo Cesari; Irene Dall'Antonia; Nico J Diederich; Kathrin Doppler; Petr Dušek; Raffaele Ferri; Jean-François Gagnon; Ziv Gan-Or; Wiebke Hermann; Birgit Högl; Michele T Hu; Alex Iranzo; Annette Janzen; Anastasia Kuzkina; Jee-Young Lee; Klaus L Leenders; Simon J G Lewis; Claudio Liguori; Jun Liu; Christine Lo; Kaylena A Ehgoetz Martens; Jiri Nepozitek; Giuseppe Plazzi; Federica Provini; Monica Puligheddu; Michal Rolinski; Jan Rusz; Ambra Stefani; Rebekah L S Summers; Dallah Yoo; Jennifer Zitser; Wolfgang H Oertel
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 44.182

9.  Cohort profile: the Oxford Parkinson's Disease Centre Discovery Cohort MRI substudy (OPDC-MRI).

Authors:  Ludovica Griffanti; Johannes C Klein; Konrad Szewczyk-Krolikowski; Ricarda A L Menke; Michal Rolinski; Thomas R Barber; Michael Lawton; Samuel G Evetts; Faye Begeti; Marie Crabbe; Jane Rumbold; Richard Wade-Martins; Michele T Hu; Clare Mackay
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

10.  Cortical gray matter progression in idiopathic REM sleep behavior disorder and its relation to cognitive decline.

Authors:  A Campabadal; A Inguanzo; B Segura; M Serradell; A Abos; C Uribe; C Gaig; J Santamaria; Y Compta; N Bargallo; C Junque; A Iranzo
Journal:  Neuroimage Clin       Date:  2020-09-09       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.